# US 2025/0367147 A1 · Solid r-beta-hydroxybutyric acid composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367147 A1
- Document ID: US20250367147A1
- Status: Published application
- Kind: A1
- Application number: 19/303,084
- Filed: 2025-08-18
- Published: 2025-12-04
- Earliest claimed: 2016-04-19
- Assignees: Axcess Global Sciences, LLC
- Applicants: Axcess Global Sciences, LLC
- Inventors: Gary MILLET; Ryan LOWERY; Jacob WILSON; Terry LACORE
- Web page: https://patentgrep.com/patent/US20250367147A1

## CPC

- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Beta-hydroxybutyric acid compositions in the form of a powder or other solid formulated for ingestion by oral delivery by mixing with water or other aqueous liquid to form a beverage that includes a liquid carrier, such as water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water, and beta-hydroxybutyrate, wherein the beta-hydroxybutyrate can be enriched in R-beta-hydroxybutyrate relative to S-beta-hydroxybutyrate, wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyric acid, S-beta-hydroxybutyric acid, and optionally one or more salts or esters of R-beta-hydroxybutyrate and one or more salts or esters S-beta-hydroxybutyrate.

## Claims

### Claim 1

A solid beta-hydroxybutyrate composition for oral delivery to increase blood ketone level in a subject, comprising:
beta-hydroxybutyric acid; and
a beta-hydroxybutyrate salt component;
wherein the composition contains a higher concentration of the beta-hydroxybutyric acid than the beta-hydroxybutyrate salt component by combined weight of the beta-hydroxybutyric acid and the beta-hydroxybutyrate salt component.

### Claim 2 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, wherein the composition contains greater than 96% and up to 99.5% of the beta-hydroxybutyric acid and from 0.5% to less than 4% of the beta-hydroxybutyrate salt component by combined weight of the beta-hydroxybutyric acid and the beta-hydroxybutyrate salt component.

### Claim 3 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, wherein the composition is a powder.

### Claim 4 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, wherein the composition is provided in a dosage form that provides a premeasured quantity of the solid beta-hydroxybutyrate composition.

### Claim 5 (depends on 3)

The solid beta-hydroxybutyrate composition of claim 3, wherein the dosage form comprises a packet or pouch.

### Claim 6 (depends on 3)

The solid beta-hydroxybutyrate composition of claim 3, wherein the dosage form comprises a tablet or capsule.

### Claim 7 (depends on 3)

The solid beta-hydroxybutyrate composition of claim 3, wherein the dosage form comprises an effervescent tablet.

### Claim 8 (depends on 3)

The solid beta-hydroxybutyrate composition of claim 3, wherein the dosage form provides a premeasured quantity of about 0.5 gram to about 25 grams of the solid beta-hydroxybutyrate composition.

### Claim 9 (depends on 3)

The solid beta-hydroxybutyrate composition of claim 3, wherein the dosage form provides a premeasured quantity of about 0.75 gram to about 20 grams of the solid beta-hydroxybutyrate composition.

### Claim 10 (depends on 3)

The solid beta-hydroxybutyrate composition of claim 3, wherein the dosage form provides a premeasured quantity of about 1 gram to about 15 grams of the solid beta-hydroxybutyrate composition.

### Claim 11 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, further comprising at least one additive selected from the group consisting of flavorant, sweetener, stabilizer, vitamin, mineral, stimulant, nootropic, edible acid, vasodilator, muscle-promoting compound, silica, effervescing agent, cannabinoid, 1,3-butanediol, beta-hydroxybutyrate ester, gelling agent, and amino acid.

### Claim 12 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, wherein the beta-hydroxybutyric acid is a non-racemic mixture enriched with R-beta-hydroxybutyric acid relative to S-beta-hydroxybutyric acid so as to contain a greater quantity of enantiomeric equivalents of R-beta-hydroxybutyric acid than S-beta-hydroxybutyric acid.

### Claim 13 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, wherein the beta-hydroxybutyric acid is a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid so as to contain a greater quantity of enantiomeric equivalents of S-beta-hydroxybutyric acid than R-beta-hydroxybutyric acid.

### Claim 14 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, wherein the beta-hydroxybutyric acid is a racemic mixture of R-beta-hydroxybutyric acid and S-beta-hydroxybutyric acid.

### Claim 15 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, wherein the beta-hydroxybutyric acid is enantiomerically pure S-beta-hydroxybutyric acid.

### Claim 16 (depends on 1)

The solid beta-hydroxybutyrate composition of claim 1, wherein the beta-hydroxybutyric acid is enantiomerically pure R-beta-hydroxybutyric acid.

### Claim 17 (depends on 1)

A kit for administering beta-hydroxybutyrate by oral delivery to increase blood ketone level in a subject to a subject, the kit comprising:
the solid beta-hydroxybutyrate composition of claim 1;
a container in which the solid beta-hydroxybutyrate composition is placed, wherein the container is selected from the group consisting of carton, box, can, jar, bag, pouch, bottle, jug, and keg; and
one or more dosage forms or measuring devices in or associated with the container and configured to provide a premeasured quantity of the solid beta-hydroxybutyrate composition, wherein the one or more dosage forms or measuring devices are selected from the group consisting of a plurality of packets, a plurality of pouches, a plurality of tablets, a plurality of effervescent tablets, a plurality of capsules, a cup, a scoop, a spatula, and a spoon.

### Claim 18

A solid beta-hydroxybutyrate composition for use in making a beverage or food for oral delivery to increase blood ketone level in a subject, comprising:
beta-hydroxybutyric acid;
a beta-hydroxybutyrate salt; and
at least one additive selected from the group consisting of flavorant, sweetener, stabilizer, vitamin, mineral, stimulant, nootropic, edible acid, vasodilator, muscle-promoting compound, silica, effervescing agent, cannabinoid, gelling agent, and amino acid, wherein the composition contains a higher concentration of the beta-hydroxybutyric acid than the beta-hydroxybutyrate salt by combined weight of the beta-hydroxybutyric acid and the beta-hydroxybutyrate salt.

### Claim 19 (depends on 17)

A kit for administering beta-hydroxybutyrate by oral delivery to increase blood ketone level in a subject to a subject, the kit comprising:
the solid beta-hydroxybutyrate composition of claim 17;
a container in which the solid beta-hydroxybutyrate composition is placed, wherein the container is selected from the group consisting of carton, box, can, jar, bag, pouch, bottle, jug, and keg; and
one or more dosage forms or measuring devices in or associated with the container and configured to provide a premeasured quantity of the solid beta-hydroxybutyrate composition, wherein the one or more dosage forms or measuring devices are selected from the group consisting of a plurality of packets, a plurality of pouches, a plurality of tablets, a plurality of effervescent tablets, a plurality of capsules, a cup, a scoop, a spatula, and a spoon.

### Claim 20

A solid beta-hydroxybutyrate composition for use in making a beverage or food for oral delivery to increase blood ketone level in a subject, comprising:
beta-hydroxybutyric acid;
a beta-hydroxybutyrate salt; and
a dosage form comprising or containing therein a unit dose of about 0.5 gram to about 50 grams by combined weight of the beta-hydroxybutyric acid and the beta-hydroxybutyrate salt, wherein the dosages form is selected from a packet, a pouch, a tablet, a capsule, and an effervescent tablet,
wherein the composition contains a higher concentration of the beta-hydroxybutyric acid than the beta-hydroxybutyrate salt by combined weight of the beta-hydroxybutyric acid and the beta-hydroxybutyrate salt.
